RT Journal Article
SR Electronic
T1 Improving SARS-CoV-2 cumulative incidence estimation through mixture modelling of antibody levels
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.09.21254250
DO 10.1101/2021.04.09.21254250
A1 Bottomley, C.
A1 Otiende, M.
A1 Uyoga, S.
A1 Gallagher, K.
A1 Kagucia, E.W.
A1 Etyang, A.O.
A1 Mugo, D.
A1 Gitonga, J.
A1 Karanja, H.
A1 Nyagwange, J.
A1 Adetifa, I.M.O.
A1 Agweyu, A.
A1 Nokes, D.J.
A1 Warimwe, G.M.
A1 Scott, J.A.G.
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.09.21254250.abstract
AB As countries decide on vaccination strategies and how to ease movement restrictions, estimates of cumulative incidence of SARS-CoV-2 infection are essential in quantifying the extent to which populations remain susceptible to COVID-19. Cumulative incidence is usually estimated from seroprevalence data, where seropositives are defined by an arbitrary threshold antibody level, and adjusted for sensitivity and specificity at that threshold. This does not account for antibody waning nor for lower antibody levels in asymptomatic or mildly symptomatic cases. Mixture modelling can estimate cumulative incidence from antibody-level distributions without requiring adjustment for sensitivity and specificity. To illustrate the bias in standard threshold-based seroprevalence estimates, we compared both approaches using data from several Kenyan serosurveys. Compared to the mixture model estimate, threshold analysis underestimated cumulative incidence by 31% (IQR: 11 to 41) on average. Until more discriminating assays are available, mixture modelling offers an approach to reduce bias in estimates of cumulative incidence.One-Sentence Summary Mixture models reduce biases inherent in the standard threshold-based analysis of SARS-CoV-2 serological data.Competing Interest StatementThe authors have declared no competing interest.Funding StatementUK Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement, which is also part of the EDCTP2 programme supported by the European Union; grant reference: MR/R010161/1 (CB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The component studies were approved by Kenya Medical Research Institute Scientific and Ethics Review Unit (Protocol SSC 3426 for blood donors and Protocol SSC 4085 for health care workers, antenatal care attendees and truck drivers). Further ethical approval for the study of antenatal care attendees was obtained from the Kenyatta National Hospital University of Nairobi Ethics Review Committee (Protocol P327/06/2020) and the Kilifi County health management rapid response team.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available on request from the corresponding author